Chemotherapy-Induced Neutropenia Treatment Market Size

Chemotherapy-Induced Neutropenia Treatment Market size was valued at USD 584.2 million in 2023 and is expected to exhibit growth at a CAGR of 3.7% from 2024 – 2032. High market growth can be attributed to the ongoing advancements in treatment options, growing use of chemotherapy, increase in the cancer incidences, and expanding healthcare expenditure in developing countries, among other contributing factors.

Moreover, the rising prevalence of cancer globally is a significant driver for the chemotherapy-induced neutropenia (CIN) treatment market. Chemotherapy is a common treatment modality for various types of cancers and neutropenia is a common side effect of chemotherapy. For instance, according to American Cancer Society, Inc. in 2023, more than 1.9 million new cancer cases were diagnosed in the U.S. As the incidence of cancer continues to increase, the demand for effective CIN treatments also rises.

Furthermore, advancements in cancer diagnosis and treatment have led to an increased utilization of chemotherapy in cancer management. Chemotherapy is employed as a curative or palliative treatment, either as a standalone therapy or in combination with surgery, radiation therapy, or targeted therapy. The expanding use of chemotherapy across various cancer types and stages contributes to a higher incidence of CIN, driving the demand for effective treatments to manage or prevent neutropenia-related complications.

Chemotherapy-induced neutropenia treatment refers to the medical interventions and supportive care measures aimed at managing or preventing neutropenia, a common side effect of chemotherapy. Neutropenia is characterized by a decrease in the number of neutrophils, a type of white blood cell that plays a crucial role in the body's immune response against infections.